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OBJECTIVES: Research has shown that a direct suggestion for a patient to schedule
an appointment encourages patients to attend their appointments more regularly,
which has a direct correlation with improved outcomes. The study’s objectives
were to determine the relationship between telephone/mail intervention and clin-
ical pharmacist appointment adherence rates; and whether patients who saw a
clinical pharmacist 3 more times had significantly different HbA1c levels com-
pared to those who did not see a clinical pharmacist.METHODS: This was a retro-
spective review of a central Texas community health center outpatient electronic
medical record from 9/1/2009-1/13/2012. Included patients were adult (18-80 years)
type 2 diabetes mellitus patients with HbA1c9. Patients with working telephone
numbers were contacted. Those who could not be reached via telephone (e.g., no
working number or no answer) or who did not schedule an appointment after the
telephone intervention were contacted by mail. Contact method type (telephone,
mail, telephone and mail), number of clinical pharmacist visits, HbA1c levels (6
months prior and one year post initial appointment) and demographics were col-
lected. Appointment adherence was calculated as kept visits/total number of pa-
tients in each contact method. RESULTS: Patients (N132) were 53.312.4 years,
52.3% female, and 72.7% Hispanic. Patients’ appointment adherence rates (raw
numbers;rate) for telephone (52/67;77.6%) were higher than mail (14/43;32.6%) and
telephone and mail (4/22;18.2%) contact methods. Although not significant
(p0.1067), the change in HbA1c from baseline to follow-up (third HbA1c) de-
creased more with patients (N40) who visited the pharmacist3 times (-2.42.2)
compared to patients (N24) who did not visit their pharmacists (-1.52.3).
CONCLUSIONS: Healthcare practitioners should consider calling or mailing type 2
diabetes patients with uncontrolled diabetes to increase appointment adherence
andhelp patients get better control of their diabetes. Patientswho saw their clinical
pharmacists 3 times had a 2.4% drop in HbA1c.
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OBJECTIVES: The objective was to analyze the disease management of diabetes in
Shanghai Minhang district and to provide evidence for improving management
practices in the future. METHODS: The program screened for diabetes in 12 com-
munity health centers with totally 943 thousands population, built up an informa-
tion system of Electronic Health Record (EHR), and conducted various forms of
follow-up visits and disease management with different time spans according to
patients’ diabetes situation. RESULTS: There were 43,709 diabetes patients man-
aged during the study period from October 2008 to September 2009, including
Type1 diabetes (T1DM), Type2 diabetes (T2DM), impaired glucose tolerance (IGT),
and impaired fasting glucose (IFG) patients. Based on the last follow-up visit during
the study period, 82.91% of managed diabetes patients monitored blood sugar reg-
ularly, while only 1.50% did not monitor at all. The percentage of patients who
monitored diet completely according to doctor’s suggestion was 81.37%. 92.91% of
type 1 diabetes patients were taking medication and the percentage of patients
using insulin was 36.32%. The percentage of type 2 diabetes patients using insulin
is only 12.37%. Based on the last follow-up visit during the study period, the average
fasting plasma glucose (FPG) was 7.051.91mmol/L and the average postprandial
plasma glucose (PPG) was 8.643.29mmol/L. The percentage of the patients whose
blood sugar level was considered to be ideal, fair, and poor was 36.12%, 32.53% and
31.34% respectively. As with HbA1C level, the number was 67.27%, 20.08% and
12.65%, although the percentage of HbA1C recorded in the system was relatively
low. CONCLUSIONS: The management of diabetes in Shanghai Minghang district
performedwell in terms of blood sugarmonitoring and diet monitoring. There was
need, however, to improve exercise involvement. The blood sugar control was not
ideal from clinical perspective, suggesting needs to improve diabetesmanagement
for blood sugar control.
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OBJECTIVES:Diet and exercise are key elements alongwith pharmacological treat-
ment to attain adequate glycemic control in diabetic persons. The aim of this study
is to identify the socio-demographic factors and attitudes associated with the fol-
lowing of diet and exercise plans in the treatment of diabetic patients at the Mex-
ican Institute of Social Security (IMSS). METHODS: Data from the institutional
health survey, encoprevenimss 2010, was used to test the statistical relationship
between socio-demographic variables and adherence to diet and exercise plans in
the treatment of diabetic patients aged 20 years and older. Two binary logistic
regression models were constructed to identify personal attitudes and socio-de-
mographic variables associated with the decision of the patient whether to follow
the recommendations. RESULTS: 31% of the patients reported fully adhering to the
prescribed diet, 25% adhered partially and 8% did not adhere to it; furthermore 27%
of the patients reported fully complying with the exercise recommendations, 16%
complied partially and 18% did not comply. At a level of significance of 5%, no
statistically significant relationship between following diet and exercise plans and
gender was found, with p-value  0.072 and 0.424 respectively. In contrast, a sta-
tistically significant relationship with age groups was obtained, p-value  0.000.
The results from the logistic regression models show that the main predictors for
whether patients would follow recommendations for diet and exercise were per-
sonal attitudes. Lack of interest or motivation regarding the importance of these
recommendations increases the probability of poor adherence. With improved
education, the probability of greater adherence to these recommendations in-
creases, while patients who work are less likely to exercise or follow the diet plan.
CONCLUSIONS: Health programs and activities aiming to motivate patients to fol-
low diet and exercise plans should be designed with special emphasis on diabetic
patients who work.
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OBJECTIVES: To improve the health outcomes and reduce costs of employees with
diabetes, many employers are initiating diabetes disease management interven-
tions. Given the variety of programs and lack of definitive guidelines reported in the
literature, identifying the most appropriate strategy can be challenging. To con-
tribute to employers’ understanding of diabetes disease management programs
and determine which are most likely to be successful, this review sought to assess
the interventions reported in the literature. METHODS: A systematic review of
PubMed, Embase and Cochrane was performed. Publications reporting the out-
comes of diabetes disease management interventions were identified. Accepted
publications were abstracted into an evidence table and included in the data
interpretation. RESULTS: In total, 37 publications met the inclusion criteria and
were included in the analysis. Nine distinct categories of diabetes management
interventionswere identified and assessed: 1) counseling by healthcare provider; 2)
group treatment management sessions; 3) education/educational materials; 4)
telephone/telemedicine support; 5) web-based support; 6) self-management sup-
port; 7) pharmacist intervention; 8) physician education/support and 9) provision
of medication or testing supplies. CONCLUSIONS: All of the diabetes disease man-
agement interventions identified by this systematic review were associated with
significantly improved health outcomes, suggesting that patients will benefit from
any strategy undertaken. Combinations of multiple interventions demonstrated
the best clinical outcomes. It was not possible, however, to determine which inter-
ventions would be most effective, given a lack of direct comparisons and potential
reporting biases.
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OBJECTIVES: The expenditures for oral anti-diabetic medications have grown
markedly over the last decade. This study examined the patterns of use and ex-
penditures of individual anti-diabetic drug classes between 1999 and 2009.
METHODS:Weobtained a 0.2% sample ofmonthly ambulatory claims fromTaiwan
National Health Insurance. We assessed volume (DDD/patient/quarter) and gov-
ernment reimbursed costs (costs/patient/quarter) for each antidiabetic drug group
over 11 years. RESULTS: Between 1999 and 2009, the number of diabetic prescrip-
tion (patient) increased steadily at an average rate of 12.2% per year. Utilization of
oral anti-diabetic drugs increased from 246.05 ddd/patient in 1999_Q1 to 334.28
ddd/patient in 2003_Q2, then began to decrease; this change was due to a marked
reduction of sulfonylureas (from 235.88 ddd/patient [79.16% of total DDDs] in
2003_Q2 to 140.37 ddd/patient [58.15% of total DDDs] in 2009_Q4). Use of biguanides
was relatively stable over the study period (average rate 61.56 ddd/patient; 23% of
the market; 646.53 NT$/patient). In 2004_Q2, there was clear shift in use from an
older gliclazide (account for 48.40% of sulfonylureas in 2004_Q2) to a newer agent,
glimepiride (24.12%). Rosiglitazone’s use (70.37% of thiazolidinediones) dropped
rapidly from 2004_Q2 due to the safety concern of cardiovascular risk. The total
costs of anti-diabetic medications increased from NT$1931.91/patient in 1999_Q1
to NT$3446.95/patient in 2004_Q2, then began to subsequently a downward trend
(NT$2380.50/patient in 2009_Q4), primarily due to a substantial reduction in thia-
zolidinediones (1,100.57 NT$/patient [29.92% of total costs] and 2004_Q2 to 569.63
NT$/patient [23.92% of total costs] in 2009_Q4). CONCLUSIONS: Sulfonylureas and
biguanides, generally recommended as first-line therapies, dominated the Taiwan
market for diabetic management (86%100% of total DDDs) over the last decade.
Uptake of newer, more expensive agents, namely thiazolidinediones and alpha-
glucosidase inhibitors, was small. Our results suggest the utilization pattern of oral
anti-diabetic medications in Taiwan is overall consistent with clinical guidelines.
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OBJECTIVES: Rapid growth of pharmaceutical costs is a major health care issue in
all countries. Taiwan has implemented several drug reimbursement rate reduc-
tions since April 2000. This research focuses on changes in use of oral antidiabetic
medications following the November 2006 price regulation. METHODS: We ob-
tained a 0.2% sample of monthly ambulatory claims from Taiwan National Health
Insurance for January 2006 through August 2007. We examined 179 products in
seven ATC categories of oral antidiabetics reimbursed, classified as either affected
A187V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
by the price reduction (“targeted”) or not (“non-targeted”). We used an interrupted
time series design and segmented regression models to estimate changes in
monthly per capita volume (DDD) and expenditures following the policy. RESULTS:
A total of 72.6% (130/179) of products were targeted by the policy. Biguanides,
sulfonylureas, alpha-glucosidase inhibitors, and thiazolidinediones accounted for
96.8% of oral antidiabetic volume and 93.3% of expenditures. After the policy, there
were reductions in the volume trend (-3.04 DDD/patient/month; 95%CI, [-4.98,
-1.10]) and expenditure trend (-61.76 NT$/patient/month; [-75.00, -48.51]) of tar-
geted medications. Growths in the market volume and expenditures for non-tar-
geted products were stable with no notable changes following the policy. Effects
differed by drug group: use of targeted biguanides remained stable, but expendi-
tures fell by 167 NT$/patient immediately after the policy; use of targeted sulfonyl-
ureas and expenditures also reduced (-2.39 DDD/patient/month [-3.00, -1.78]; 204
NT$/patient immediately after the policy); and use of targeted thiazolidinediones
decreased (-0.58 DDD/patient/month [-0.81, -0.35]). In contrast, use and expendi-
tures for non-targeted biguanides and alpha-glucosidase inhibitors increased,
while non-targeted sulfonylureas remained stable. CONCLUSIONS: Overall, the
price reduction policy resulted in lower use and expenditures for targeted oral
antidiabetics medications, but reductions in market growth for several classes of
targeted products and increases in use of non-targeted products. Our results sug-
gest that the price reduction impacts may differ among specific anti-diabetic drug
groups.
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OBJECTIVES: Individuals with diabetes are particularly susceptible to influenza
and pneumonia infection. They are recommended to receive annual influenza
vaccination during flu season and at least one pneumonia shot during lifetime. The
Healthy People 2010 Initiative set a goal of vaccinating 90% of those diabetic adults
over 65 years old and 60% among diabetic patients less than 65 years of age. Vac-
cination coverage among diabetic adults in the United States, however, is
understudied. METHODS: We analyzed the 2006-2010 National Health Interview
Survey (NHIS) data to 1) estimate the influenza and pneumococcal vaccine cover-
age rates among adults with diabetes over the 5-year study period adjusting for
weights, and 2) identify factors that are potentially associated with both vaccina-
tions among this population using multiple logistic regression. RESULTS: Among
diabetic adults aged 18 to 64 years old, both influenza and pneumonia vaccination
coverage decreased in 2007 and increased steadily from 2008 (weighted estimates:
47.5% for influenza and 32.2% for pneumonia) to 2010 (weighted estimates: 53.4%
for influenza and 38.2% for pneumonia). For those aged 65 years or older, influenza
vaccination coverage was relatively stable from 2006 to 2009 but reduced in 2010.
Pneumonia vaccination rates did not vary much from 2006 to 2010. Overall, both
coverage levels were substantially higher among the aged group. Factors that pos-
itively associated with vaccinationwere 65 years or older, high school education or
above, being married, having a health insurance, formal smoking, longer duration
of being diabetic, having at least one comorbid chronic condition, having more
than 2 physician encounters in last 12 months. CONCLUSIONS: The influenza and
pneumonia vaccination coverage increased marginally among adults with diabe-
tes from 2006 to 2010 but the objective of Health People 2010 had not achieved yet.
Special efforts could be implemented to enhance both vaccine coverage among
diabetic adults.
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OBJECTIVES: Opioid use has grown over the last decade and neuropathy and dia-
betic peripheral neuropathy (DPN) guidelines do not recommend opioids as first
line treatment. This study sought to examine the proportion of DPN patients who
are prescribed opioids and to determine the proportion of DPN patients who are
prescribed opioids as first line treatment.METHODS:A 10% sample of IMS-LifeLink
claims data from 1998 through 2008 were used. The study population consisted of
patients with 1 diagnosis for diabetes and/or 1 claim for an antidiabetic pre-
scription. DPN patients were identified with a validated DPN identification algo-
rithm; and the first date of a DPN diagnosis served as the index date. All patients
were required to have continuous 12 month pre- and post index date plan enroll-
ment and be 17 years of age. Patients with cancer, non-cancer pain conditions,
surgery in the pre- and post- 12 month index period, and with opioid use in the
pre-index period were excluded. Descriptive statistics including demographic
Charlson-comorbidities, with first line use of DPN related medications were
calculated. RESULTS: A total of 984 DPN patients met inclusion exclusion criteria
with a mean age of 60.08 years. 37.40% were female and 29.88% used insulin. 428
DPN patients (43.49%) received DPN pharmacologic treatment. Of those with DPN
pharmacologic treatments, 91 (21.26%) received opioid as first line treatment. An-
tidepressants, anticonvulsants and NSAIDs were initially used by 28.97%, 23.60%,
and 21.96% respectively. The most commonly used opioids were hydrocodone
combinations (8.03%), followed by codeine combinations (2.64%) and oxycodoneCR
(2.44%). Factors associated with opioid use will be reported. CONCLUSIONS: Over
50% of DPN patients remained untreated with pharmacologic therapy after a DPN
diagnosis, which may reflect under-treatment. Despite DPN treatment guidelines
that do not recommend opioids as first line treatment, opioids were among the
most common first line agents used.
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OBJECTIVES: To explore the association between race and the use of Thiazolidin-
ediones (TZDs) and metformin among patients with Type II diabetes in the Mary-
land Medicaid population. METHODS: Medical/prescription/enrollment records
from the Maryland State Medicaid Managed Care Organization/Fee-for-service,
ages 18 or older, initiating use of either metformin or TZDs between 7-1-05 and
12-31-09, followed for 6months. Variations in race over TZDs andmetformin use
are described. Logistic regressions assess the likelihood of 1) starting on TZDs over
metformin, and 2) switching to a TZD given initial use ofmetformin. Models adjust
for other anti-diabetic agents, demographics, and comorbidities: hyptertension
(HTN), hyperlipidemia (HLD), liver disease (LD), renal dysfunction (RD). RESULTS:A
total of 25,758 started on metformin (N19910) or TZDs (N5848). 20% of patients
started on metformin used TZDs later, and 47% of patients started on TZDs used
metformin later. 24% of Caucasians (N8570), 21.5% of African-Americans
(N14094), 22% of Hispanics (N987), and 28.6% of other races (N1,201) were
started on TZDs. 20% of Caucasians started onmetformin switched to TZDs; as did
18% of African-Americans, 22% of Hispanics, and 24% of other races. Logistic re-
gression shows that African-Americans (OR0.88, 95%CI: 0.82-0.95) and Hispanics
(OR0.80, CI: 0.68-0.95) were less likely than Caucasians to be started on TZDs.
Males (OR0.92, CI: 0.86-0.98) were less likely than women, likelihood of initiation
on TZD increases with age or RD (OR1.91, CI: 1.62-2.25), and decreases if HTN
(OR0.64, CI: 0.59-0.69), HLD (OR0.68, CI: 0.62-0.74), or LD (OR0.48, CI: 0.37-0.63)
are present. Therewas no association between race and the likelihood of switching
to TZD once started onmetformin. There was no evidence of sample selection bias
in the lattermodel. CONCLUSIONS:Minority diabetic patients were less likely than
Caucasians to be started on TZDs rather than metformin.
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OBJECTIVES: Compare patient characteristics, medication use, diabetes-related
charges, and resource utilization between patients with Type 2 diabetes (T2DM)
who initiated therapy with an oral fixed combination (OFC) therapy and those
treated with two medications which are available in OFC formulation (dual).
METHODS:Data for this studywere obtained from the i3 inVision™databases over
the time period from January 1, 2006 through June 30, 2010. The analyses compares
patients who initiated therapy on an OFC (N4271) to those who initiated on two
classes of oral medications which are available in an OFC combination (N1780).
Patients were followed for 2 years post initiation and all analyses are descriptive in
nature.RESULTS: Patientswho initiated on anOFC, compared to those treatedwith
dual oral medications, were less likely to be diagnosed with a microvascular
(14.17% vs. 17.02%: p0.0046) or macrovascular (10.68% vs. 14.21%; P0.0001) com-
plication in the pre-period, although they weremore likely to be prescribed an ACE
(11.59 vs. 7.64%; P0.0001), ARB (9.58% vs. 4,44%; P0.0001), or statin (13.28% vs.
10.67%; P0.0001) in the pre-period. Use of OFC, compared to use of dual therapies,
was associated with a significant reduction in post-period hospitalization rates
(15.83% vs. 21.80%; P0.0001) as well as a lower likelihood of an ER visit (2.39% vs.
3.48%; P0.0168) and lower diabetes-related inpatient ($2174 v $3034; P0.0020),
outpatient ($2490 vs. $2,870; P0.0042), drug ($1576 vs. $2084; P0.0001) and total
charges ($6,250 v $8,019; P0.0001). Use of an OFC was associated with a signifi-
cantly higher medication possession ratio (0.58 vs. 0.51; P0.0001) and such pa-
tients were less likely to have a gap in the medication therapy of 60 days or more
(32.76% vs. 37.81%; P0.0002). CONCLUSIONS: The use of an OFC was associated
with improved patient adherence and lower diabetes-related charges compared
the dual cohort.
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OBJECTIVES: To investigate insulin injection treatment patterns and treatment
restrictions, in particular nurse administered insulin injections, on Type 2Diabetes
(T2D) patients receiving care from home healthcare agencies (HHAs), skilled nurs-
ing facilities (SNFs), and veterans affairs (VA) facilities in the United States.
METHODS: Medical directors and other knowledgeable clinical personnel from 67
HHAs, 60 SNFs, and 49 VA facilities completed online surveys in December 2008 to
January 2009 and in December 2010 to January 2011. The VA surveys covered three
VA settings: medical/surgical inpatient (VA-MS), mental health/substance abuse
inpatient (VA-MH/SA), and adult day rehabilitation (VA-ADR). RESULTS:Amajority
(67%) of HHA respondents reported that patients received one injection per day,
while two injections per daywas themost commonly reported number among SNF
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